# Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

> **NCT05827081** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 1400 (estimated)

## Conditions studied

- Early Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Letrozole
- **DRUG:** Ansastrozole
- **DRUG:** Goserelin
- **DRUG:** Leuprolide
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT05827081
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-28
- **Primary completion:** 2029-09-07
- **Final completion:** 2030-09-20
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05827081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05827081, "Phase IIIb Study of Ribociclib + ET in Early Breast Cancer". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT05827081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*